Serveur d'exploration sur les peptides biopesticides

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Preventive effect of several drugs against Pseudomonas aeruginosa infection and the toxicity of combined tumor necrosis factor with lipopolysaccharide: relationship between lethality and the arachidonic cascade.

Identifieur interne : 004307 ( Main/Exploration ); précédent : 004306; suivant : 004308

Preventive effect of several drugs against Pseudomonas aeruginosa infection and the toxicity of combined tumor necrosis factor with lipopolysaccharide: relationship between lethality and the arachidonic cascade.

Auteurs : N. Satomi [Japon] ; A. Sakurai ; F. Iimura ; R. Haranaka ; K. Haranaka

Source :

RBID : pubmed:2169830

Descripteurs français

English descriptors

Abstract

The participation of tumor necrosis factor (TNF) and lipopolysaccharide (LPS) in Pseudomonas aeruginosa (Pa) infection was examined. The lethal challenge of Pa or TNF and LPS injection could be prevented by pretreatment with anti-TNF antibody, polymyxin B, ONO 1078, or Shosaiko-to. The combined effects of TNF and LPS may be deeply related to the lethality of Pa infection. The activities of leukotriene(LT) C4/D4/E4 or platelet activating factor (PAF) were also related to the lethality of Pa infection, probably due to the subsequently produced TNF which acts in combination with LPS. Activating the host defence mechanism with biological response modifiers like Chinese medicines was effective against Pa infection. One mechanism could involve an activity as an LT inhibitor or PAF antagonist. Following the administration of TNF and/or LPS, the serum levels of arachidonic cascade products underwent various changes. With a combination of TNF and LPS, there was a synergistic increment of prostaglandins, thromboxane, and LT. Following pretreatment with Shosaiko-to, suppression of LTs was dominant even with the combination of TNF and LPS, which might be related to the lethality of the infection or combined TNF with LPS.

DOI: 10.1007/BF02173524
PubMed: 2169830


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Preventive effect of several drugs against Pseudomonas aeruginosa infection and the toxicity of combined tumor necrosis factor with lipopolysaccharide: relationship between lethality and the arachidonic cascade.</title>
<author>
<name sortKey="Satomi, N" sort="Satomi, N" uniqKey="Satomi N" first="N" last="Satomi">N. Satomi</name>
<affiliation wicri:level="4">
<nlm:affiliation>Department of Internal Medicine, University of Tokyo, Japan.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Internal Medicine, University of Tokyo</wicri:regionArea>
<placeName>
<settlement type="city">Tokyo</settlement>
<region type="province">Région de Kantō</region>
</placeName>
<orgName type="university">Université de Tokyo</orgName>
</affiliation>
</author>
<author>
<name sortKey="Sakurai, A" sort="Sakurai, A" uniqKey="Sakurai A" first="A" last="Sakurai">A. Sakurai</name>
</author>
<author>
<name sortKey="Iimura, F" sort="Iimura, F" uniqKey="Iimura F" first="F" last="Iimura">F. Iimura</name>
</author>
<author>
<name sortKey="Haranaka, R" sort="Haranaka, R" uniqKey="Haranaka R" first="R" last="Haranaka">R. Haranaka</name>
</author>
<author>
<name sortKey="Haranaka, K" sort="Haranaka, K" uniqKey="Haranaka K" first="K" last="Haranaka">K. Haranaka</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="1990">1990</date>
<idno type="RBID">pubmed:2169830</idno>
<idno type="pmid">2169830</idno>
<idno type="doi">10.1007/BF02173524</idno>
<idno type="wicri:Area/Main/Corpus">004319</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">004319</idno>
<idno type="wicri:Area/Main/Curation">004319</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">004319</idno>
<idno type="wicri:Area/Main/Exploration">004319</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Preventive effect of several drugs against Pseudomonas aeruginosa infection and the toxicity of combined tumor necrosis factor with lipopolysaccharide: relationship between lethality and the arachidonic cascade.</title>
<author>
<name sortKey="Satomi, N" sort="Satomi, N" uniqKey="Satomi N" first="N" last="Satomi">N. Satomi</name>
<affiliation wicri:level="4">
<nlm:affiliation>Department of Internal Medicine, University of Tokyo, Japan.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Internal Medicine, University of Tokyo</wicri:regionArea>
<placeName>
<settlement type="city">Tokyo</settlement>
<region type="province">Région de Kantō</region>
</placeName>
<orgName type="university">Université de Tokyo</orgName>
</affiliation>
</author>
<author>
<name sortKey="Sakurai, A" sort="Sakurai, A" uniqKey="Sakurai A" first="A" last="Sakurai">A. Sakurai</name>
</author>
<author>
<name sortKey="Iimura, F" sort="Iimura, F" uniqKey="Iimura F" first="F" last="Iimura">F. Iimura</name>
</author>
<author>
<name sortKey="Haranaka, R" sort="Haranaka, R" uniqKey="Haranaka R" first="R" last="Haranaka">R. Haranaka</name>
</author>
<author>
<name sortKey="Haranaka, K" sort="Haranaka, K" uniqKey="Haranaka K" first="K" last="Haranaka">K. Haranaka</name>
</author>
</analytic>
<series>
<title level="j">Biotherapy (Dordrecht, Netherlands)</title>
<idno type="ISSN">0921-299X</idno>
<imprint>
<date when="1990" type="published">1990</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Aminoglycosides (MeSH)</term>
<term>Animals (MeSH)</term>
<term>Anti-Bacterial Agents (therapeutic use)</term>
<term>Antibodies (therapeutic use)</term>
<term>Antineoplastic Agents (therapeutic use)</term>
<term>Antineoplastic Combined Chemotherapy Protocols (pharmacology)</term>
<term>Antineoplastic Combined Chemotherapy Protocols (toxicity)</term>
<term>Arachidonic Acid (MeSH)</term>
<term>Arachidonic Acids (blood)</term>
<term>Cephamycins (therapeutic use)</term>
<term>Chromones (therapeutic use)</term>
<term>Drug Synergism (MeSH)</term>
<term>Drugs, Chinese Herbal (therapeutic use)</term>
<term>Female (MeSH)</term>
<term>Leukotriene Antagonists (MeSH)</term>
<term>Leukotriene E4 (MeSH)</term>
<term>Lipopolysaccharides (administration & dosage)</term>
<term>Lipopolysaccharides (toxicity)</term>
<term>Mice (MeSH)</term>
<term>Mice, Inbred Strains (MeSH)</term>
<term>Platelet Activating Factor (antagonists & inhibitors)</term>
<term>Polymyxin B (therapeutic use)</term>
<term>Pseudomonas Infections (blood)</term>
<term>Pseudomonas Infections (prevention & control)</term>
<term>Recombinant Proteins (toxicity)</term>
<term>SRS-A (analogs & derivatives)</term>
<term>SRS-A (antagonists & inhibitors)</term>
<term>SRS-A (blood)</term>
<term>SRS-A (metabolism)</term>
<term>Tumor Necrosis Factor-alpha (administration & dosage)</term>
<term>Tumor Necrosis Factor-alpha (immunology)</term>
<term>Tumor Necrosis Factor-alpha (toxicity)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>4H-1-Benzopyran-4-ones (usage thérapeutique)</term>
<term>Acide arachidonique (MeSH)</term>
<term>Acides arachidoniques (sang)</term>
<term>Aminosides (MeSH)</term>
<term>Animaux (MeSH)</term>
<term>Antagonistes des leucotriènes (MeSH)</term>
<term>Antibactériens (usage thérapeutique)</term>
<term>Anticorps (usage thérapeutique)</term>
<term>Antinéoplasiques (usage thérapeutique)</term>
<term>Céfamycines (usage thérapeutique)</term>
<term>Facteur d'activation plaquettaire (antagonistes et inhibiteurs)</term>
<term>Facteur de nécrose tumorale alpha (administration et posologie)</term>
<term>Facteur de nécrose tumorale alpha (immunologie)</term>
<term>Facteur de nécrose tumorale alpha (toxicité)</term>
<term>Femelle (MeSH)</term>
<term>Infections à Pseudomonas (prévention et contrôle)</term>
<term>Infections à Pseudomonas (sang)</term>
<term>Leucotriène E4 (MeSH)</term>
<term>Lignées consanguines de souris (MeSH)</term>
<term>Lipopolysaccharides (administration et posologie)</term>
<term>Lipopolysaccharides (toxicité)</term>
<term>Médicaments issus de plantes chinoises (usage thérapeutique)</term>
<term>Polymyxine B (usage thérapeutique)</term>
<term>Protocoles de polychimiothérapie antinéoplasique (pharmacologie)</term>
<term>Protocoles de polychimiothérapie antinéoplasique (toxicité)</term>
<term>Protéines recombinantes (toxicité)</term>
<term>Souris (MeSH)</term>
<term>Substances à réaction différée de l'anaphylaxie (analogues et dérivés)</term>
<term>Substances à réaction différée de l'anaphylaxie (antagonistes et inhibiteurs)</term>
<term>Substances à réaction différée de l'anaphylaxie (métabolisme)</term>
<term>Substances à réaction différée de l'anaphylaxie (sang)</term>
<term>Synergie des médicaments (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en">
<term>Lipopolysaccharides</term>
<term>Tumor Necrosis Factor-alpha</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en">
<term>SRS-A</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en">
<term>Platelet Activating Factor</term>
<term>SRS-A</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en">
<term>Arachidonic Acids</term>
<term>SRS-A</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en">
<term>Tumor Necrosis Factor-alpha</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en">
<term>SRS-A</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en">
<term>Anti-Bacterial Agents</term>
<term>Antibodies</term>
<term>Antineoplastic Agents</term>
<term>Cephamycins</term>
<term>Chromones</term>
<term>Drugs, Chinese Herbal</term>
<term>Polymyxin B</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="toxicity" xml:lang="en">
<term>Lipopolysaccharides</term>
<term>Recombinant Proteins</term>
<term>Tumor Necrosis Factor-alpha</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en">
<term>Aminoglycosides</term>
<term>Arachidonic Acid</term>
<term>Leukotriene Antagonists</term>
<term>Leukotriene E4</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr">
<term>Facteur de nécrose tumorale alpha</term>
<term>Lipopolysaccharides</term>
</keywords>
<keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr">
<term>Substances à réaction différée de l'anaphylaxie</term>
</keywords>
<keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr">
<term>Facteur d'activation plaquettaire</term>
<term>Substances à réaction différée de l'anaphylaxie</term>
</keywords>
<keywords scheme="MESH" qualifier="blood" xml:lang="en">
<term>Pseudomonas Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr">
<term>Facteur de nécrose tumorale alpha</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr">
<term>Substances à réaction différée de l'anaphylaxie</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr">
<term>Protocoles de polychimiothérapie antinéoplasique</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacology" xml:lang="en">
<term>Antineoplastic Combined Chemotherapy Protocols</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en">
<term>Pseudomonas Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr">
<term>Infections à Pseudomonas</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr">
<term>Acides arachidoniques</term>
<term>Infections à Pseudomonas</term>
<term>Substances à réaction différée de l'anaphylaxie</term>
</keywords>
<keywords scheme="MESH" qualifier="toxicity" xml:lang="en">
<term>Antineoplastic Combined Chemotherapy Protocols</term>
</keywords>
<keywords scheme="MESH" qualifier="toxicité" xml:lang="fr">
<term>Facteur de nécrose tumorale alpha</term>
<term>Lipopolysaccharides</term>
<term>Protocoles de polychimiothérapie antinéoplasique</term>
<term>Protéines recombinantes</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr">
<term>4H-1-Benzopyran-4-ones</term>
<term>Antibactériens</term>
<term>Anticorps</term>
<term>Antinéoplasiques</term>
<term>Céfamycines</term>
<term>Médicaments issus de plantes chinoises</term>
<term>Polymyxine B</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Animals</term>
<term>Drug Synergism</term>
<term>Female</term>
<term>Mice</term>
<term>Mice, Inbred Strains</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr">
<term>Acide arachidonique</term>
<term>Aminosides</term>
<term>Animaux</term>
<term>Antagonistes des leucotriènes</term>
<term>Femelle</term>
<term>Leucotriène E4</term>
<term>Lignées consanguines de souris</term>
<term>Souris</term>
<term>Synergie des médicaments</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">The participation of tumor necrosis factor (TNF) and lipopolysaccharide (LPS) in Pseudomonas aeruginosa (Pa) infection was examined. The lethal challenge of Pa or TNF and LPS injection could be prevented by pretreatment with anti-TNF antibody, polymyxin B, ONO 1078, or Shosaiko-to. The combined effects of TNF and LPS may be deeply related to the lethality of Pa infection. The activities of leukotriene(LT) C4/D4/E4 or platelet activating factor (PAF) were also related to the lethality of Pa infection, probably due to the subsequently produced TNF which acts in combination with LPS. Activating the host defence mechanism with biological response modifiers like Chinese medicines was effective against Pa infection. One mechanism could involve an activity as an LT inhibitor or PAF antagonist. Following the administration of TNF and/or LPS, the serum levels of arachidonic cascade products underwent various changes. With a combination of TNF and LPS, there was a synergistic increment of prostaglandins, thromboxane, and LT. Following pretreatment with Shosaiko-to, suppression of LTs was dominant even with the combination of TNF and LPS, which might be related to the lethality of the infection or combined TNF with LPS.</div>
</front>
</TEI>
<pubmed>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">2169830</PMID>
<DateCompleted>
<Year>1990</Year>
<Month>11</Month>
<Day>15</Day>
</DateCompleted>
<DateRevised>
<Year>2019</Year>
<Month>10</Month>
<Day>29</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0921-299X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>2</Volume>
<Issue>3</Issue>
<PubDate>
<Year>1990</Year>
</PubDate>
</JournalIssue>
<Title>Biotherapy (Dordrecht, Netherlands)</Title>
<ISOAbbreviation>Biotherapy</ISOAbbreviation>
</Journal>
<ArticleTitle>Preventive effect of several drugs against Pseudomonas aeruginosa infection and the toxicity of combined tumor necrosis factor with lipopolysaccharide: relationship between lethality and the arachidonic cascade.</ArticleTitle>
<Pagination>
<MedlinePgn>227-34</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>The participation of tumor necrosis factor (TNF) and lipopolysaccharide (LPS) in Pseudomonas aeruginosa (Pa) infection was examined. The lethal challenge of Pa or TNF and LPS injection could be prevented by pretreatment with anti-TNF antibody, polymyxin B, ONO 1078, or Shosaiko-to. The combined effects of TNF and LPS may be deeply related to the lethality of Pa infection. The activities of leukotriene(LT) C4/D4/E4 or platelet activating factor (PAF) were also related to the lethality of Pa infection, probably due to the subsequently produced TNF which acts in combination with LPS. Activating the host defence mechanism with biological response modifiers like Chinese medicines was effective against Pa infection. One mechanism could involve an activity as an LT inhibitor or PAF antagonist. Following the administration of TNF and/or LPS, the serum levels of arachidonic cascade products underwent various changes. With a combination of TNF and LPS, there was a synergistic increment of prostaglandins, thromboxane, and LT. Following pretreatment with Shosaiko-to, suppression of LTs was dominant even with the combination of TNF and LPS, which might be related to the lethality of the infection or combined TNF with LPS.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Satomi</LastName>
<ForeName>N</ForeName>
<Initials>N</Initials>
<AffiliationInfo>
<Affiliation>Department of Internal Medicine, University of Tokyo, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sakurai</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Iimura</LastName>
<ForeName>F</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Haranaka</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Haranaka</LastName>
<ForeName>K</ForeName>
<Initials>K</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Netherlands</Country>
<MedlineTA>Biotherapy</MedlineTA>
<NlmUniqueID>8903031</NlmUniqueID>
<ISSNLinking>0921-299X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000617">Aminoglycosides</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000906">Antibodies</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D001095">Arachidonic Acids</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D002513">Cephamycins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D002867">Chromones</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004365">Drugs, Chinese Herbal</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D020024">Leukotriene Antagonists</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008070">Lipopolysaccharides</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010972">Platelet Activating Factor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D013189">SRS-A</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C461320">shosaiko-to</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>27YG812J1I</RegistryNumber>
<NameOfSubstance UI="D016718">Arachidonic Acid</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>75715-89-8</RegistryNumber>
<NameOfSubstance UI="D017999">Leukotriene E4</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>7JHD84H15J</RegistryNumber>
<NameOfSubstance UI="C023384">fortimicin A</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>J2VZ07J96K</RegistryNumber>
<NameOfSubstance UI="D011112">Polymyxin B</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>T0785J3X40</RegistryNumber>
<NameOfSubstance UI="C035978">cefbuperazone</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>TB8Z891092</RegistryNumber>
<NameOfSubstance UI="C047681">pranlukast</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName UI="D000617" MajorTopicYN="Y">Aminoglycosides</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000906" MajorTopicYN="N">Antibodies</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
<QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D016718" MajorTopicYN="N">Arachidonic Acid</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D001095" MajorTopicYN="N">Arachidonic Acids</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D002513" MajorTopicYN="N">Cephamycins</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D002867" MajorTopicYN="N">Chromones</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D004365" MajorTopicYN="N">Drugs, Chinese Herbal</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D020024" MajorTopicYN="Y">Leukotriene Antagonists</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D017999" MajorTopicYN="N">Leukotriene E4</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008070" MajorTopicYN="N">Lipopolysaccharides</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008815" MajorTopicYN="N">Mice, Inbred Strains</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D010972" MajorTopicYN="N">Platelet Activating Factor</DescriptorName>
<QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D011112" MajorTopicYN="N">Polymyxin B</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D011552" MajorTopicYN="N">Pseudomonas Infections</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName>
<QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D013189" MajorTopicYN="N">SRS-A</DescriptorName>
<QualifierName UI="Q000031" MajorTopicYN="N">analogs & derivatives</QualifierName>
<QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="pubmed">
<Year>1990</Year>
<Month>1</Month>
<Day>1</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>1990</Year>
<Month>1</Month>
<Day>1</Day>
<Hour>0</Hour>
<Minute>1</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>1990</Year>
<Month>1</Month>
<Day>1</Day>
<Hour>0</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">2169830</ArticleId>
<ArticleId IdType="doi">10.1007/BF02173524</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations>
<list>
<country>
<li>Japon</li>
</country>
<region>
<li>Région de Kantō</li>
</region>
<settlement>
<li>Tokyo</li>
</settlement>
<orgName>
<li>Université de Tokyo</li>
</orgName>
</list>
<tree>
<noCountry>
<name sortKey="Haranaka, K" sort="Haranaka, K" uniqKey="Haranaka K" first="K" last="Haranaka">K. Haranaka</name>
<name sortKey="Haranaka, R" sort="Haranaka, R" uniqKey="Haranaka R" first="R" last="Haranaka">R. Haranaka</name>
<name sortKey="Iimura, F" sort="Iimura, F" uniqKey="Iimura F" first="F" last="Iimura">F. Iimura</name>
<name sortKey="Sakurai, A" sort="Sakurai, A" uniqKey="Sakurai A" first="A" last="Sakurai">A. Sakurai</name>
</noCountry>
<country name="Japon">
<region name="Région de Kantō">
<name sortKey="Satomi, N" sort="Satomi, N" uniqKey="Satomi N" first="N" last="Satomi">N. Satomi</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Bois/explor/BiopestPeptidV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004307 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004307 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Bois
   |area=    BiopestPeptidV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:2169830
   |texte=   Preventive effect of several drugs against Pseudomonas aeruginosa infection and the toxicity of combined tumor necrosis factor with lipopolysaccharide: relationship between lethality and the arachidonic cascade.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:2169830" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a BiopestPeptidV1 

Wicri

This area was generated with Dilib version V0.6.38.
Data generation: Thu Nov 19 19:22:35 2020. Site generation: Thu Nov 19 19:33:26 2020